Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

DVAX 14.29 -0.22 (-1.52%)
price chart
Dynavax Technologies Q2 Loss Wider than Expected, Sales Beat
Dynavax Technologies Corporation (DVAX - Snapshot Report) reported a loss of 9 cents per share in the second quarter of 2014, flat with the year-ago quarter but wider than the Zacks Consensus Estimate of a loss of 6 cents.
Related articles »  
Dynavax Technologies Corporation (DVAX): Dynavax: Embarking On A Run ...
Dynavax (NASDAQ:DVAX) will require a lot of patience. The stock will require about as much patience as has ever been asked of you as an investor.
Dynavax: Assembling The A-Team
As I noted earlier this year, on Thursday, March 21, 2013, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that David Novack joined the company as its Senior Vice President, Operations and Quality, effective March 25, 2013.
Related articles »  
Hedge Funds Are Crazy About Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation To the average investor, there are dozens of gauges shareholders can use to track publicly traded companies.
Dynavax: FDA Asks For Additional Safety Data  Seeking Alpha
Dynavax's hepatitis B vaccine delayed as FDA seeks more data  Reuters
Related articles »  
Company Announcements: Dynavax Technologies , Infinity Pharmaceuticals
Dynavax Technologies Corporation (NASDAQ:DVAX) : Announced that the independent Data and Safety Monitoring Board, or DSMB, charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational ...
Could Dynavax Technologies Corporation(NASDAQ:DVAX), Alpha Natural ...
Dynavax Technologies Corporation(NASDAQ:DVAX) is a California-based clinical-stage biopharmaceutical company that discovers and develops products that are used to treat cancer and infectious and inflammatory diseases.
Related articles »  
Dynavax Technologies Corporation (DVAX) news: Dynavax drops request for ...
Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less ...
Dynavax Withdraws MAA on Heplisav  Zacks.com
Dynavax Withdraws MAA on Heplisav - Analyst Blog  NASDAQ
Related articles »  
Dynavax Technologies Corporation (DVAX): Insiders Are Buying Dynavax
In Europe, Dynavax' Marketing Authorization Application for Heplisav is currently under review by the European Medicines Agency.
Dynavax Technologies Corporation (DVAX): Getting Ultra-Bullish On Dynavax
Dynavax Technologies Corporation is a clinical-stage biopharma that develops novel products to prevent and treat infectious and inflammatory diseases and cancer.
Related articles »  
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United ...
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), ...
Related articles »